CoLucid Pharmaceuticals colucid.com


Public list: BIO 2016 (619) Pharma Startups (6570) Neuroscience Startups (947)

CoLucid Pharmaceuticals (NASDAQ: CLCD) aims to advance drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's pipeline includes lasmiditan, a treatment for migraine headache. Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans. Lasmiditan is a member of a drug class ca...Show all

CoLucid Pharmaceuticals (NASDAQ: CLCD) aims to advance drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's pipeline includes lasmiditan, a treatment for migraine headache. Lasmiditan is a first...Show all

Company (Acquired)

Phone: 919-649-6184

Fax:

2520 Meridian Parkway
Suite 400
Durham, 27713
North Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
CoLucid Pharmaceuticals $86.9M Mar 1, 2017
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related CoLucid Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 10 investors

Competitors

Company Status Description Investors

Alexza Pharmaceuticals

Mountain View, California, United States
AcquiredAlexza is developing drugs for acute and intermittent medical conditions. Their Staccato system aerosolizes without thermal degradation, enabling convenient delivery and rapid therapeutic onset of many small molecule drugs. The company has product candidates in clinical trials for migraine headaches, acute panic attacks, acute agitation in schizophrenia and acute pain.Login to see details

KAI Pharmaceuticals

South San Francisco, California, United States
AcquiredKAI Pharmaceuticals is a privately held, venture-backed drug discovery and development company with preclinical and clinical programs in acute cardiovascular and other diseases representing unmet medical needs. The company has applied its core expertise in the biology of PKC to develop highly potent and selective inhibitors and activators for each of the PKC isozymes for the treatment of a broad array of human diseases. KAI has received Fast-Track designation from the FDA for its lead compound, ...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Compositions and methods of synthesis of pyridinolypiperidine 5-ht1f agonists Mar 31, 2011 Apr 15, 2014 Patent
Compounds that inhibit cholinesterase Feb 04, 2008 Jan 24, 2012 Patent